Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.74 |
| ▸ | KDR | P35968 | 11/20 | 0.61 |
| ▸ | SRC | P12931 | 9/20 | 0.61 |
| ▸ | BRAF | P15056 | 8/20 | 0.61 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.53 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.53 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6177947 | 0.85 | MAPK14 (1.00) | MAPK14KDRSRCBRAFRIPK2 | |
| SCHEMBL5255663 | 0.83 | MAPK14 (0.51) | MAPK14KDRSRCBRAFRIPK2 | |
| SCHEMBL1800179 | 0.77 | MAPK14 (0.43) | MAPK14KDRSRCBRAFRIPK2 | |
| SCHEMBL14839384 | 0.76 | BRAF (1.00) | MAPK14KDRSRCBRAFRIPK2 | |
| SCHEMBL20075458 | 0.76 | ADORA2A (0.43) | MAPK14KDRSRCRIPK2EGFR | |
| SCHEMBL6180875 | 0.75 | MAPK14 (0.60) | MAPK14KDRSRCBRAFRIPK2 | |
| SCHEMBL19926278 | 0.75 | MAPT (0.68) | MAPK14KDRSRCBRAFMAPT | |
| SCHEMBL5254957 | 0.74 | PDE2A (0.49) | MAPK14KDRSRCBRAFMAPK11 | |
| SCHEMBL26713552 | 0.74 | MAPK14 (0.58) | MAPK14KDRSRCBRAFMAPK11 | |
| SCHEMBL5258683 | 0.71 | SRC (0.46) | MAPK14KDRSRCBRAFRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147579-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2004-07-29 | — | — | US | claimed |
| US-20020086869-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2002-07-04 | — | — | US | claimed |
| US-6335336-B1 | TREATING TUMOR NECROSIS FACTOR AND MITOGEN-ACTIVATED PROTEIN KINASE(MAP) MEDIATED DISORDERS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; INFLAMMATORY BOWEL DISEASE | G.D. SEARLE & COMPANY | 2002-01-01 | — | — | US | claimed |
| CN-1264376-A | 3(5)-Heteroaryl substituted pyrazoles as P38 kinase inhibitors | SEARLE & CO (US) | 2000-08-23 | — | — | CN | claimed |
| US-6087496-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-07-11 | — | — | US | claimed |
| EP-0983260-A2 | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998052937-A2 | 4-ARYL-3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS P38 KINASE | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | claimed |
| US-7019005-B2 | 3 (5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & CO. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040147579-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2004-07-29 | — | — | US | disclosed |
| US-6579873-B2 | Treatment of inflammation, arthritis, bone disorders, respiratory system disorders | PHARMACIA CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020086869-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2002-07-04 | — | — | US | disclosed |
| US-6335336-B1 | TREATING TUMOR NECROSIS FACTOR AND MITOGEN-ACTIVATED PROTEIN KINASE(MAP) MEDIATED DISORDERS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; INFLAMMATORY BOWEL DISEASE | G.D. SEARLE & COMPANY | 2002-01-01 | — | — | US | disclosed |
| CN-1264376-A | 3(5)-Heteroaryl substituted pyrazoles as P38 kinase inhibitors | SEARLE & CO (US) | 2000-08-23 | — | — | CN | disclosed |
| US-6087496-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-1001934-A1 | INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 2000-05-24 | — | — | EP | disclosed |
| EP-0983260-A2 | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-03-08 | — | — | EP | disclosed |
| US-5932576-A | USEFUL FOR TREATING P38 KINASE MEDIATED DISORDERS SUCH AS ATHEROSCLEROSIS, RHEUMATIOD ARTHRITIS, INFLAMMATORY BOWEL DISEASE, PSORIASIS AND OTHERS | G. D. SEARLE & COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999005104-A1 | INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-02-04 | — | — | WO | disclosed |
| WO-1998052937-A2 | 4-ARYL-3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS P38 KINASE | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147579-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | MAPK1, MAPKAPK2, MAPK3 | MAPK14 26/4885KDR 2306/4885SRC 742/4885 |
| US-20020086869-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | MAPK1, MAPKAPK2, MAPK3 | MAPK14 26/4885KDR 2306/4885SRC 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.